title: Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
abstract: BACKGROUND
  : Elderly patients with acute myeloid leukemia (AML) have a poor prognosis, which is explained by the disease itself and by host-related factors. The objective of this study was to determine the prognostic role of comorbidities in this population.
  
  
  METHODS
  : For this single-center, retrospective study, the authors analyzed the outcome of 133 patients aged >/=70 years who received induction chemotherapy for nonpromyelocytic AML between 1995 and 2004. Comorbidities were evaluated by using an adapted form of the Charlson comorbidity index (CCI).
  
  
  RESULTS
  : The median patient age was 73 years. The CCI score was 0 for 83 patients (68%), 1 for 16 patients (13%), and >1 for 23 patients (19%). The complete remission (CR) rate was 56%, and the median overall survival was 9 months. In multivariate analysis, 4 adverse prognostic factors for CR were identified: unfavorable karyotype, leukocytosis >/=30 g/L, CD34 expression on leukemic cells, and CCI >1. A score could be generated to allow the stratification of patients into low-, intermediate-, and high-risk groups with CR rates of 87%, 63%, and 37%, respectively. The risk of early mortality and the probability of survival also were different in the 3 risk groups (P = .02 and P = .01, respectively).
  
  
  CONCLUSIONS
  : The results from this study indicated that associated comorbidities are independent factors that may influence achievement of CR in elderly patients with AML. Such a scoring system may be useful in the prognostic staging systems that are used to identify patients with AML who can benefit from induction chemotherapy.
authors.affiliation: Department of Hematology, Paoli-Calmettes Institute, Marseille, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Etienne
authors.forename: Benjamin
authors.initials: B
authors.lastname: Esterni
authors.forename: Aude
authors.initials: A
authors.lastname: Charbonnier
authors.forename: Marie-Joëlle
authors.initials: MJ
authors.lastname: Mozziconacci
authors.forename: Christine
authors.initials: C
authors.lastname: Arnoulet
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.forename: Brigitte
authors.initials: B
authors.lastname: Puig
authors.forename: Jean-Albert
authors.initials: JA
authors.lastname: Gastaut
authors.forename: Dominique
authors.initials: D
authors.lastname: Maraninchi
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015897:Comorbidity; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate